Alcobra Pharmaceuticals

Indonesia
Kador, Riau, Indonesia
+972 72-220-4661 ★

Company profile

Alcobra Pharmaceuticals company profile

Alcobra Pharmaceuticals Inc., which is developing a treatment for attention deficit hyperactivity disorder (ADHD) held its Nasdaq IPO last night (Israel time). Sources said that the company had obtained positive feedback during its road show. Just before the road show, the company expanded its prospectus from issuing 1.36 million share to 2.27 million shares. Alcobra held the offering at $8 per share, raising a gross $25 million at a company value of $89 million. The company had hoped to raise the money at a share proce of between $10 and $12. It will be traded under the ticker "ADHD".

Business identity

Contact email
[email protected]
Phone number
+972 72-220-4661
Operating status
Closed
Company type
For Profit
Employee range
00011-00050 employees
Founded
2008-01-01

Headquarters

Headquarters
Kador, Riau, Indonesia
Country code
ID
Continent
Asia

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
1
Total equity funding
$8.2M
Last funding
Post Ipo Equity / $8.2M / 2014-03-01
Last equity funding
Post Ipo Equity / $8.2M
Investors
1
Founders
2
Exited on
2013-05-21

Founders and investors

Founders

Dalia MegiddoUdi Gilboa

Investors

Cybele Holdings

People at this company

Preview only. Contact details are available after you sign in.

Log in to view people and contact details at this company

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Sign in to view shipment history, products, suppliers, and trade lanes for this company.

Log in to view shipment data

Shipment records and coverage can change as the dataset is updated.